Be Ready to Expedite Treatment for Malignant Hyperthermia

February 2018

Hospitals are striving to meet expectations for treating malignant hyperthermia.

About one in 2,000 people are at risk for malignant hyperthermia from exposure to anesthetic gases (desflurane, etc) or succinylcholine.

These patients can have muscle rigidity, hyperthermia, tachycardia, or hypercapnia from uncontrolled calcium release in the muscle...which can lead to rhabdomyolysis, arrhythmias, acute kidney injury, and death.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Med Safety Limit the Use of Injectable Promethazine in Your Hospital
Kidney Disease Help Ensure the Safe Use of Secondary Hyperparathyroid Meds
Anesthesia Be Ready to Expedite Treatment for Malignant Hyperthermia
Critical Care Use Best Practices for Your Targeted Temperature Management Protocols
Interactions Contact Your Lab if Patients Report High Biotin Use
New Drugs Stay Alert for New GLP-1 Agonists and Flozins During Transitions of Care
New Drugs Help Avoid Errors With the New HIV Drug, Juluca
Monitoring Help Answer Questions About Using Continuous Glucose Monitors in the Hospital
Cardiology Help Optimize Medication Management for Stable Coronary Artery Disease
Travel Medicine Be Prepared to Treat Patients With Altitude Illness
New Drugs Stay Alert for New GLP-1 Agonists and Flozins During Transitions of Care
New Drugs Help Avoid Errors With the New HIV Drug, Juluca

Be Ready to Expedite Treatment for Malignant Hyperthermia

Get unlimited access through an Enterprise license

Table of Contents